Financial Security Advisor Inc. Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Financial Security Advisor Inc. acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the third quarter, HoldingsChannel reports. The fund acquired 2,475 shares of the medical equipment provider’s stock, valued at approximately $202,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Innealta Capital LLC acquired a new stake in Hologic during the second quarter valued at approximately $25,000. Wolff Wiese Magana LLC bought a new stake in Hologic during the third quarter worth approximately $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic in the first quarter valued at $37,000. Sunbelt Securities Inc. bought a new position in Hologic during the second quarter valued at about $37,000. Finally, Cromwell Holdings LLC lifted its holdings in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on HOLX shares. JPMorgan Chase & Co. lifted their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday. Royal Bank of Canada upped their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday. Mizuho reduced their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday. UBS Group raised their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and cut their target price for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Trading Down 5.9 %

Shares of Hologic stock opened at $78.80 on Wednesday. Hologic, Inc. has a 52 week low of $66.93 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The stock has a 50 day moving average price of $81.05 and a two-hundred day moving average price of $78.11. The stock has a market capitalization of $18.30 billion, a PE ratio of 26.80, a price-to-earnings-growth ratio of 2.98 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the previous year, the company earned $0.89 earnings per share. The company’s quarterly revenue was up 4.5% on a year-over-year basis. As a group, equities analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.